5 Fascinating Facts About Pfizer

The vaccine originally came under development in April 2020, when Pfizer announced its partnership with German biotechnology company BioNTech. BioNTech contributed mRNA vaccine candidates, while Pfizer led the charge with clinical research and development of the vaccine, as well as manufacturing and distribution.

On Dec. 11, 2020, the mRNA two-dose vaccine was officially cleared for use in the U.S.; and just a week later, Moderna’s vaccine was also cleared. Between these two vaccines and the Johnson & Johnson vaccine, 424 million doses of COVID-19 vaccine have been administered, reaching 58.1% of the American population, according to Our World in Data.

Pfizer continued its expansion, and in 1980 began selling an anti-inflammatory drug called Feldene — its first product to reach $1 billion in sales. Before 2000, the company grew by marketing drugs such as Zoloft, Lipitor, Norvasc and Viagra, and has since reached unprecedented levels of success through multiple acquisitions and a consumer healthcare division.Although Pfizer is clearly worth a lot of money — $215.

Still, there are plenty of experts urging investors to stake their claim in Pfizer. The company has sustained setbacks both with its legacy drugs and with recent clinical studies on a breast cancer drug, but the success of the COVID-19 vaccine is expected to propel the stock higher.Despite producing a successful COVID-19 vaccine, Pfizer made $41.9 billion in 2020; an increase of only 2% from its 2019 revenue. But there are good reasons for this.

Frank D’Amelio, Pfizer’s CFO, has claimed that once the pandemic shifts into an “endemic” state — essentially, when most places are vaccinated, restricting COVID-19 cases to certain pockets of the world — it will create an opportunity for Pfizer to increase the pricing of its vaccine. This will likely make it harder for low-resource communities to get vaccinated.

I think this is what’s called a puff piece

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pfizer says COVID-19 pill cut hospital, death risk by 90%Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it. Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results.
Source: YahooSG - 🏆 3. / 71 Read more »

Pfizer says antiviral pill cuts risk of severe Covid-19 by 89%NEW YORK — A trial of Pfizer's experimental antiviral pill for Covid-19 was stopped early after the drug was shown to cut by 89 per cent the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday (Nov 5). Pfizer , you have with so many hospitalised cases, plenty of candidates to continue the trial to make sure the results is beyond doubt.
Source: TODAYonline - 🏆 1. / 99 Read more »